RU2018136872A - Композиции, содержащие 15-oh эпк, и способы их применения - Google Patents

Композиции, содержащие 15-oh эпк, и способы их применения Download PDF

Info

Publication number
RU2018136872A
RU2018136872A RU2018136872A RU2018136872A RU2018136872A RU 2018136872 A RU2018136872 A RU 2018136872A RU 2018136872 A RU2018136872 A RU 2018136872A RU 2018136872 A RU2018136872 A RU 2018136872A RU 2018136872 A RU2018136872 A RU 2018136872A
Authority
RU
Russia
Prior art keywords
epa
pharmaceutical composition
subject
fatty acids
acids present
Prior art date
Application number
RU2018136872A
Other languages
English (en)
Russian (ru)
Inventor
Джонатан РОУ
Кевин ДАФФИ
Джон КЛАЙМАКС
Original Assignee
Эфиммьюн Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эфиммьюн Лимитед filed Critical Эфиммьюн Лимитед
Publication of RU2018136872A publication Critical patent/RU2018136872A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
RU2018136872A 2013-01-30 2014-01-24 Композиции, содержащие 15-oh эпк, и способы их применения RU2018136872A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1301626.6A GB201301626D0 (en) 2013-01-30 2013-01-30 Composition comprising 15-OHEPA and methods of using the same
GBGB1301626.6 2013-01-30

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2015136849A Division RU2671208C2 (ru) 2013-01-30 2014-01-24 Композиции, содержащие 15-он эпк, и способы их применения

Publications (1)

Publication Number Publication Date
RU2018136872A true RU2018136872A (ru) 2018-11-27

Family

ID=47891001

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2018136872A RU2018136872A (ru) 2013-01-30 2014-01-24 Композиции, содержащие 15-oh эпк, и способы их применения
RU2015136849A RU2671208C2 (ru) 2013-01-30 2014-01-24 Композиции, содержащие 15-он эпк, и способы их применения

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2015136849A RU2671208C2 (ru) 2013-01-30 2014-01-24 Композиции, содержащие 15-он эпк, и способы их применения

Country Status (27)

Country Link
US (6) US20150224076A1 (enExample)
EP (2) EP3058943B1 (enExample)
JP (2) JP6363104B2 (enExample)
KR (6) KR20230047201A (enExample)
CN (2) CN105120872B (enExample)
AU (2) AU2014211628B2 (enExample)
BR (1) BR112015018270A2 (enExample)
CA (1) CA2897343C (enExample)
CY (1) CY1117209T1 (enExample)
DK (1) DK2762143T3 (enExample)
ES (2) ES2564025T3 (enExample)
GB (1) GB201301626D0 (enExample)
HR (1) HRP20160203T1 (enExample)
HU (1) HUE026901T2 (enExample)
IL (3) IL239893A (enExample)
MX (2) MX364646B (enExample)
NZ (1) NZ709803A (enExample)
PH (1) PH12015501582B1 (enExample)
PL (1) PL2762143T3 (enExample)
PT (1) PT2762143E (enExample)
RS (1) RS54584B1 (enExample)
RU (2) RU2018136872A (enExample)
SG (2) SG10201806854XA (enExample)
SI (1) SI2762143T1 (enExample)
SM (1) SMT201600069B (enExample)
WO (1) WO2014118097A1 (enExample)
ZA (2) ZA201505018B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
JP2016538288A (ja) 2013-11-15 2016-12-08 ディグニティ サイエンシス リミテッド 多価不飽和ヒドロキシ脂肪酸の薬学的に許容される塩
CA2935986A1 (en) * 2014-01-10 2015-07-16 Mehar Manku Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
MA41120A (fr) 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
HK1247136A1 (zh) * 2015-01-16 2018-09-21 Afimmune Limited 包含15-hepe的组合物和其使用方法
CN115025079A (zh) 2015-04-28 2022-09-09 普罗诺瓦生物医药挪威公司 结构增强的含硫脂肪酸在预防和/或治疗非酒精性脂肪性肝炎中的用途
HK1250345A1 (zh) 2015-05-13 2018-12-14 Afimmune Limited 包含15-氧代-epa或15-氧代-dgla的组合物及其制备和使用方法
EP3861995A1 (en) * 2015-07-21 2021-08-11 Affimune Limited Compositions comprising 15-hepe for use in treating or preventing neurologic disease
BR122023026625A2 (pt) 2015-12-18 2024-01-16 Afimmune Limited Uso do ácido 15-hidroxieicosapentaenoico ou derivados farmaceuticamente aceitáveis do mesmo
CA3084728A1 (en) 2017-12-06 2019-06-13 Basf As Fatty acid derivatives for treating non-alcoholic steatohepatitis
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
CN115215725A (zh) * 2021-04-15 2022-10-21 宋晓瑜 一种制备乙酸薰衣草酯及薰衣草醇的方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05186342A (ja) * 1992-01-10 1993-07-27 Fujirebio Inc 免疫調節作用を併せもつ抗炎症剤
AU673700B2 (en) 1993-01-27 1996-11-21 Scotia Holdings Plc Triglycerides
BR9405620A (pt) 1993-10-01 1999-09-08 Scherer Corp R P Cápsula de gelatina contendo fragr‰ncia, e, processo para sua preparação
US20020055539A1 (en) * 1996-10-02 2002-05-09 Bockow Barry I. Compositions and methods for treating cardiovascular conditions
WO1999058120A1 (en) * 1998-05-08 1999-11-18 Rolf Berge USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS
JP2000191525A (ja) 1998-12-25 2000-07-11 Nof Corp 皮膚外用剤組成物
ATE344226T1 (de) 2000-02-16 2006-11-15 Brigham & Womens Hospital Aspirin-ausgelöste lipidmediatoren
US20040043013A1 (en) 2000-12-28 2004-03-04 Mccleary Edward Larry Metabolic uncoupling therapy
ES2238568T3 (es) 2001-05-30 2005-09-01 Laxdale Limited Uso del coenzima q (ubiquinona) y acido eicosapentaenoico (epa) para el tratamiento del linfoma no hodgkin y trastornos psiquiatricos o neurologicos.
CN1250230C (zh) * 2001-09-30 2006-04-12 中国药品生物制品检定所 海狗油作为制备治脂肪肝药的应用
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
JP2005179211A (ja) 2003-12-17 2005-07-07 Idemitsu Kosan Co Ltd 皮膚外用剤組成物
GB2409644B (en) 2003-12-31 2005-12-21 Igennus Ltd Formulation comprising eicosapentaenoic acid or an ester thereof and a triterpene or an ester thereof
US20050239889A1 (en) 2004-04-26 2005-10-27 Jean Gosselin In vivo release of endogenous anti-microbial mediators by leukotriene B4 (LTB4) administration
US20050282781A1 (en) 2004-06-18 2005-12-22 Shibnath Ghosal Compositions of stable bioactive metabolites of docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids
CN101043884A (zh) 2004-07-01 2007-09-26 谢彭斯眼科研究公司 用于治疗眼部疾病和病症的组合物和方法
US20090182022A1 (en) * 2006-01-05 2009-07-16 Reliant Pharmaceuticals Treatment of Fatty Liver
ES2527438T3 (es) 2006-08-08 2015-01-26 Metabolon, Inc. Marcadores de la hepatopatía grasa no alcohólica (NAFLD) y de la esteatohepatitis no alcohólica (NASH) y métodos de uso de los mismos
US20100120914A1 (en) * 2007-03-30 2010-05-13 Kowa Company, Ltd. Medicament for prophylactic and/or therapeutic treatment of hepatic steatosis or non-alcoholic steatohepatitis
GB0802116D0 (en) 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
WO2009154230A1 (ja) * 2008-06-17 2009-12-23 持田製薬株式会社 非アルコール性脂肪肝炎の予防／改善・治療薬
US8853437B2 (en) * 2009-02-20 2014-10-07 The University Of Tokyo Anti-inflammatory compounds
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
CA2690488C (en) 2010-01-19 2013-06-11 Accucaps Industries Limited Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof
JP5909183B2 (ja) * 2010-08-19 2016-04-26 国立大学法人 東京大学 オメガ３系脂肪酸由来の新規抗炎症性代謝物
WO2012031125A2 (en) 2010-09-01 2012-03-08 The General Hospital Corporation Reversal of general anesthesia by administration of methylphenidate, amphetamine, modafinil, amantadine, and/or caffeine
US10154977B2 (en) 2011-03-25 2018-12-18 The Brigham And Women's Hospital, Inc. Anti-inflammatory particles
US20120264824A1 (en) 2011-04-15 2012-10-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US8936803B2 (en) 2011-10-19 2015-01-20 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and/or 15-HETrE and methods of use thereof
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
CA2856715A1 (en) 2011-11-29 2013-06-06 Dignity Sciences Limited Compositions comprising 20-carbon fatty acids and methods of making and using same
JP6399655B2 (ja) 2012-01-06 2018-10-03 オムセラ・ファーマシューティカルズ・インコーポレイテッド 遊離酸型のオメガ−３多価不飽和脂肪酸のｄｐａ濃縮組成物
US20120264705A1 (en) * 2012-01-26 2012-10-18 Dignity Sciences Limited Antimicrobial compositions comprising 15-hetre and methods of use thereof
US20130267598A1 (en) 2012-02-23 2013-10-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
JP6370775B2 (ja) * 2012-05-10 2018-08-08 ソルテックス エヌエー エルエルシー 天然の特異的炎症収束性メディエータおよびその前駆物質を含有する、抗炎症活性を有する油
GB201213484D0 (en) * 2012-07-30 2012-09-12 Dignity Sciences Ltd Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
MA41120A (fr) * 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
EP3861995A1 (en) * 2015-07-21 2021-08-11 Affimune Limited Compositions comprising 15-hepe for use in treating or preventing neurologic disease
BR122023026625A2 (pt) 2015-12-18 2024-01-16 Afimmune Limited Uso do ácido 15-hidroxieicosapentaenoico ou derivados farmaceuticamente aceitáveis do mesmo

Also Published As

Publication number Publication date
CN105120872B (zh) 2020-01-10
KR20150112995A (ko) 2015-10-07
HUE026901T2 (en) 2016-07-28
EP2762143B1 (en) 2015-12-02
US20150224076A1 (en) 2015-08-13
BR112015018270A2 (pt) 2017-07-18
KR20220119524A (ko) 2022-08-29
JP2016511753A (ja) 2016-04-21
EP2762143A1 (en) 2014-08-06
GB201301626D0 (en) 2013-03-13
KR20250105691A (ko) 2025-07-08
ES2564025T3 (es) 2016-03-17
HK1200351A1 (en) 2015-08-07
US20220347147A1 (en) 2022-11-03
CN111214464A (zh) 2020-06-02
PL2762143T3 (pl) 2016-06-30
AU2014211628B2 (en) 2018-04-19
HRP20160203T1 (hr) 2016-03-25
PT2762143E (pt) 2016-03-28
AU2014211628A1 (en) 2015-07-30
WO2014118097A1 (en) 2014-08-07
CY1117209T1 (el) 2017-04-05
KR102274963B1 (ko) 2021-07-08
KR102434817B1 (ko) 2022-08-19
JP6363104B2 (ja) 2018-07-25
ES2759448T3 (es) 2020-05-11
US20200069626A1 (en) 2020-03-05
IL239893A0 (en) 2015-08-31
IL239893A (en) 2017-04-30
IL251639A0 (en) 2017-06-29
SG10201806854XA (en) 2018-09-27
MX2019005082A (es) 2019-08-12
ZA201605125B (en) 2018-06-27
MX364646B (es) 2019-05-03
US10813903B2 (en) 2020-10-27
SI2762143T1 (sl) 2016-04-29
RS54584B1 (sr) 2016-08-31
KR20240011872A (ko) 2024-01-26
US20210228524A1 (en) 2021-07-29
SMT201600069B (it) 2016-04-29
CA2897343A1 (en) 2014-08-07
US20250186384A1 (en) 2025-06-12
US20210244697A1 (en) 2021-08-12
CN105120872A (zh) 2015-12-02
MX2015009803A (es) 2015-10-29
RU2671208C2 (ru) 2018-10-30
RU2015136849A (ru) 2017-03-06
EP3058943A1 (en) 2016-08-24
JP2018172409A (ja) 2018-11-08
KR102514913B1 (ko) 2023-03-27
ZA201505018B (en) 2017-01-25
KR20210088733A (ko) 2021-07-14
PH12015501582A1 (en) 2015-10-05
AU2018206685A1 (en) 2018-08-02
DK2762143T3 (en) 2016-03-07
NZ709803A (en) 2020-05-29
EP3058943B1 (en) 2019-09-25
SG11201505457PA (en) 2015-08-28
PH12015501582B1 (en) 2019-10-25
KR20230047201A (ko) 2023-04-06
CA2897343C (en) 2021-03-16
IL265876A (en) 2019-06-30

Similar Documents

Publication Publication Date Title
RU2018136872A (ru) Композиции, содержащие 15-oh эпк, и способы их применения
HRP20210686T1 (hr) Pripravci i postupci za liječenje moždanog udara kod subjekta na istodobnoj terapiji statinom
RU2018133298A (ru) Способы применения агонистов fxr
EA201790124A1 (ru) Соли берберина, соли урсодезоксихолевой кислоты и их комбинации, способы получения и применения
RU2018111327A (ru) Способ ингибирования всасывания и/или повышения выведения липидов с использованием d-псикозы
CN104187627B (zh) 一种降血脂组合物及其在制备具有降血脂功能的保健食品中的应用
JP2015503590A5 (enExample)
RU2019110980A (ru) Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением
JP2016511753A5 (enExample)
WO2010121128A3 (en) Compositions and methods for treating or inhibiting liver injury
JP2015038135A5 (enExample)
RU2017112149A (ru) Комбинация омега-3 жирной кислоты и SGLT-2 ингибитора для лечения болезней печени
WO2011118976A3 (en) Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same
JP2022031813A (ja) １５－ｈｅｐｅを含む組成物、およびそれを用いて線維症を処置または防止する方法
JP2023065454A (ja) １５－オキソ－ｅｐａまたは１５－オキソ－ｄｇｌａを含む組成物、ならびにその作製及び使用方法
RU2016129079A (ru) Композиции омега-3 жирных кислот для лечения заболеваний, вызывающих поражение нервной системы
EA201990883A1 (ru) Соли берберина, соли урсодезоксихолевой кислоты и их комбинации, способы получения и применения
RU2020121222A (ru) Агонисты fxr для лечения заболеваний печени
JP2017530142A5 (enExample)
EA201100682A1 (ru) Стабильная фармацевтическая композиция, содержащая прегабалин, капсула, ее содержащая, способ получения и применение
RU2013126798A (ru) Комбинированная терапия дексаметазоном
EA201592261A1 (ru) Фармацевтические композиции, включающие агомелатин в форме сокристаллов агомелатина с органической кислотой
RU2020110253A (ru) Экстракт s. spinosum для лечения жировой болезни печени
RU2011108011A (ru) Применение полидатина для лечения заболеваний печени и фармацевтическая композиция на основе полидатина
EA201592159A1 (ru) Применение тиазолопиримидинона для лечения воспалительного заболевания кишечника

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20170125